WAKEFIELD, Mass., Sept. 28, 2020 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading vertically integrated cannabis operator in the United States, today announced management is scheduled to participate in the following upcoming investor conference events:

NEW YORK, Sept. 25, 2020 /PRNewswire/ — The legalization of cannabis in several countries is one of the key factors driving the market’s growth. In addition, the use of cannabis for medical purposes is gaining momentum worldwide. Medical cannabis products are used for the treatment of various chronic conditions such as cancer, arthritis, and neurological conditions, as well as anxiety, depression, epilepsy, as well as Parkinson’s and Alzheimer’s disease. This year, the elections across the country will help determine the future of cannabis products in several states and could have an influence on the federal legalization in the future. According to Leafy, six states will be voting on legalization this November, with four states are voting on adult-use (recreational) cannabis legalization: Arizona, Montana, New Jersey, and South Dakota. Two states are voting on medical marijuana legalization: Mississippi, and South Dakota. Oregon voters will consider two separate drug reform measures. One would legalize the medical use of psilocybin. The other would decriminalize small amounts of all drugs. MediPharm Labs Corp. (OTC: MEDIF) (TSX: LABS), HEXO Corp. (NYSE: HEXO), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), OrganiGram Holdings Inc. (OGI), GW Pharmaceuticals plc (NASDAQ: GWPH)